Sourcing and CoAs: how to verify a peptide is what the label says

Sourcing is the dominant safety variable

Pharmacology is what the molecule does. Sourcing determines whether you actually got the molecule. In the research-peptide market, the distance between those two questions is much wider than people realize. Independent testing programs have repeatedly found vials labeled as one peptide that contain a different peptide, the right peptide at a fraction of the labeled dose, or unidentified material entirely.

If you take away one thing from this guide: every vial you put into your body should be backed by a recent, batch-specific Certificate of Analysis from a third-party lab. No CoA, no inject.

What a real Certificate of Analysis looks like

A legitimate CoA names a specific lot number, dates the analysis, identifies the lab that ran it, and reports at minimum two things: identity (the molecule is what the label claims) and purity (how much of the sample is the target peptide vs related impurities).

• HPLC (high-performance liquid chromatography) — separates the components and reports purity as a percentage. >95% is the floor for research-grade; >98% is good.
• Mass spectrometry (MS) — confirms identity by measuring the molecular weight of the peptide. The reported mass should match the theoretical mass for the sequence within a small tolerance.
• Batch / lot number — must match the number printed on the vial you received. A CoA from a different lot tells you nothing about your vial.
• Date of analysis — within the last 12 months at most. Older CoAs are reused as marketing material long after the actual batch is gone.
• Lab identity — third-party labs name themselves. 'Internal QC' is not third-party.

Red flags in the supplier itself

Patterns that correlate strongly with bad product:

• Prices materially below the market floor. Synthesis has a real cost; selling a 10 mg BPC-157 vial for $8 means the math does not work unless the contents are not BPC-157.
• No batch-specific CoAs, or CoAs that look photoshopped (font mismatches, blurry headers, mismatched dates).
• Aggressive 'human use' marketing dressed up in research-compound language. Legitimate suppliers stay on the legal side of the line.
• No physical address, no phone number, no company-name continuity across years.
• Heavy reliance on influencer codes and Telegram-only channels with no public storefront.
• Refusal to disclose the synthesis origin — most research peptides are made in China or India and reshipped; refusing to discuss the supply chain is itself a signal.
• Inconsistent packaging across orders — different label fonts, different vial sizes for the 'same' product.

Adulteration: what actually gets found

Independent testing programs (most notably Janoshik Analytical, who tests research peptide vendors for free in return for publication) have documented every failure mode at least once: under-dosed vials, wrong peptide, wrong sequence, bacterial endotoxin levels above injection-safe thresholds, residual solvents above pharmacopeia limits, and in a small number of cases vials that contained only mannitol filler.

The practical defense is layered: pick a vendor with a long public testing record, cross-reference any specific lot number you have against third-party results when possible, and treat any sensory anomaly (off color, particles, unusual smell on reconstitution) as a hard stop.

A sourcing checklist you can actually use

Run every order through this list. If a vendor or product fails more than one item, walk.

• Vendor publishes batch-specific CoAs from a named third-party lab, dated within the last 12 months.
• CoA includes both HPLC purity (>95%) and mass-spec identity confirmation.
• Lot number on the CoA matches the lot number on your vial.
• Public testing history (Janoshik, MZ Biolabs, or similar) exists across multiple products over multiple months.
• Pricing is within the market band — not the cheapest, not the most expensive.
• Packaging is consistent across orders: same label design, same vial spec, same cap color.
• Reconstituted product is clear and colorless (with rare known exceptions like GHK-Cu, which is blue).
• Vendor responds to written questions about supply chain without defensiveness.

Endotoxin and sterility

Bacterial endotoxin is the most underappreciated risk in research peptides. Endotoxin is a fragment of the outer membrane of Gram-negative bacteria; it survives autoclaving, it does not require a live bacterial contamination to be present, and it produces fever, malaise, and at high enough doses systemic inflammatory response. Pharmacopeia limits exist (USP <85>) and good research suppliers test against them. If a CoA does not mention endotoxin, ask. If the answer is evasive, that is your answer.